DDInter1042 DDInter364
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Chlorpropamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Chlorpropamide is not recommended for the treatment of NIDDM as it increases blood pressure and the risk of retinopathy (UKPDS-33). Up to 80% of the single oral dose of chlorpropramide is metabolized, likely in the liver; 80-90% of the dose is excreted in urine as unchanged drug and metabolites. Renal and hepatic dysfunction may increase the risk of hypoglycemia.
Chlorpropamide {u} (Compound) resembles {v} (Compound) Sulfacetamide
Chlorpropamide {u} (Compound) resembles {v} (Compound) Gliclazide
Chlorpropamide {u} (Compound) treats {v} (Disease) type 2 diabetes mellitus
Chlorpropamide {u} (Compound) binds {v} (Gene) SLC15A1
Chlorpropamide {u} (Compound) is included by {v} (Pharmacologic Class) Sulfonylurea Compounds
Chlorpropamide {u} (Compound) causes {v} (Side Effect) Water retention
Chlorpropamide (Compound) resembles Sulfacetamide (Compound)
Chlorpropamide (Compound) resembles Gliclazide (Compound)
Chlorpropamide (Compound) treats type 2 diabetes mellitus (Disease)
Chlorpropamide (Compound) binds SLC15A1 (Gene)
Chlorpropamide (Compound) is included by Sulfonylurea Compounds (Pharmacologic Class)
Chlorpropamide (Compound) causes Water retention (Side Effect)